Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma

Korean J Intern Med. 2014 Mar;29(2):250-2. doi: 10.3904/kjim.2014.29.2.250. Epub 2014 Feb 27.

Authors

Ha-young Lee¹, Kyung Hee Lee², Myung Soo Hyun², Min Kyoung Kim², Sung Ae Koh², Hee Soon Cho³

Affiliations

¹ Division of Hematology and Oncology, Department of Internal Medicine, Cancer Center Dongnam Institute Radiological and Medical Sciences, Busan, Korea.
² Division of Hematology and Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
³ Department of Laboratory Medicine, Yeungnam University College of Medicine, Daegu, Korea.

No abstract available

Keywords: Chronic myeloid leukemia; Diffuse large B-cell lymphoma; Therapy-related.

Publication types

Case Reports
Letter
Review

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Benzamides / therapeutic use
Bone Marrow Examination
Chemoradiotherapy
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Humans
Imatinib Mesylate
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / pathology
Lymphoma, Large B-Cell, Diffuse / therapy
Male
Neoplasms, Second Primary*
Piperazines / therapeutic use
Positron-Emission Tomography
Prednisolone / administration & dosage
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / therapeutic use
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Vincristine / administration & dosage
Whole Body Imaging / methods

Substances

Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Vincristine
Doxorubicin
Imatinib Mesylate
Cyclophosphamide
Prednisolone

Supplementary concepts

VAP-cyclo protocol